The short answer: Peptides are short chains of amino acids that act as signalling molecules. A small number are FDA-approved drugs with strong randomized evidence — semaglutide, tirzepatide, tesamorelin, and PT-141 among them. The large majority sold as "peptide therapy" are research-use-only compounds with animal or small-sample human data only, and several were placed on the FDA 503A/503B compounding exclusion lists. Evidence grade, regulatory status, and sourcing quality matter more than the mechanism story on any vendor website.
Peptide therapy has become one of the fastest-growing corners of wellness medicine, and one of the least disciplined. The same list will contain a drug with a 17,000-patient cardiovascular outcomes trial next to a compound whose entire human evidence base is one open-label study of nineteen people. This guide grades each class honestly, states where the regulatory line sits, and explains what to ask before starting.
Peptide candidacy quiz
Eight questions on goals, medical history, and risk tolerance. You get a 0–100 score, a candidacy band, and an honest read on whether a peptide is the right tool for what you are trying to fix. No email required.
Treatment comparison table
8 options, with the effect reported in trials, how fast it arrives, the evidence grade, and an honest verdict — including the ones that do not work.
| Treatment | Class | Effect | First benefit | Evidence | Side effects | Verdict |
|---|---|---|---|---|---|---|
| Semaglutide | FDA-approved | About 15% mean body weight reduction at 68 weeks | 2–4 wksfull effect ~68 wks | A — multiple RCTsSTEP 1 (n=1,961) and SELECT (n=17,604) — weight and cardiovascular outcomes. | Nausea, vomiting, constipation, gallbladder events. | The strongest evidence base of any peptide in clinical use. |
| Tirzepatide | FDA-approved | About 21% mean body weight reduction at 72 weeks | 2–4 wksfull effect ~72 wks | A — multiple RCTsSURMOUNT-1 (n=2,539) and the SURPASS diabetes programme. | Gastrointestinal, dose-escalation dependent. | Largest weight effect size demonstrated in a randomized trial. |
| Tesamorelin | FDA-approved | About 15% reduction in visceral adipose tissue | 8–12 wksfull effect ~26 wks | A — multiple RCTsTwo phase 3 trials in HIV-associated lipodystrophy (n>800 combined). | Injection-site reaction, arthralgia, raised IGF-1, glucose intolerance. | Approved for a narrow indication. Off-label use in healthy adults lacks safety data. |
| Bremelanotide (PT-141) | FDA-approved | Statistically significant but modest improvement in desire scores | 1–4 wksfull effect ~12 wks | B — RCT or strong cohortRECONNECT trials in premenopausal hypoactive sexual desire disorder. | Nausea, flushing, headache, transient blood pressure rise. | Real but modest effect, approved only in premenopausal women. |
| BPC-157 | Research-use only | No randomized human evidence | 0 wkfull effect ~0 wks | D — no reliable benefitExtensive rodent tendon and gut healing data; no completed randomized human trial. | Unknown in humans. FDA placed it in compounding category 2 in 2023. | Popular, plausible, and unproven in people. Not legally compoundable. |
| Ipamorelin / CJC-1295 | Research-use only | Raises growth hormone pulses; clinical outcomes unproven | 4–8 wksfull effect ~0 wks | D — no reliable benefitPharmacokinetic and GH-secretion studies; no outcome trials in healthy adults. | Water retention, raised IGF-1, glucose intolerance. Long-term safety unknown. | Raising a hormone is not the same as improving an outcome. Category 2 compounding list. |
| Thymosin alpha-1 | Research-use only | Immunomodulatory; approved in some countries, not the US | 4–12 wksfull effect ~26 wks | C — limited or mixedTrials in hepatitis B and sepsis, largely outside the US; mixed quality. | Injection-site reaction; theoretical autoimmune risk. | The best-evidenced of the non-approved immune peptides, which is a low bar. |
| Epitalon | Research-use only | No credible human evidence | 0 wkfull effect ~0 wks | D — no reliable benefitSmall Russian-language studies from the 1990s and 2000s; telomerase claims unreplicated. | Unknown. Compounding category 2. | Marketed as a longevity peptide on evidence that would not pass modern review. |
When each treatment starts working
The most common reason a treatment "fails" is stopping before it has had time to work. The bar shows the window in which trials report first noticeable benefit; the marker shows full effect.
- Bremelanotide (PT-141)first benefit wks 1–4 · full ~wk 12
- Semaglutidefirst benefit wks 2–4 · full ~wk 68
- Tirzepatidefirst benefit wks 2–4 · full ~wk 72
- Tesamorelinfirst benefit wks 8–12 · full ~wk 26
What peptides are, and what they are not
A peptide is a chain of amino acids shorter than a protein — typically fewer than fifty residues. Insulin is a peptide. So is glucagon-like peptide 1, the molecule semaglutide mimics. Peptides act as signalling molecules: they bind receptors and change cellular behaviour, which is why the mechanism stories are usually plausible.
Plausible mechanism is not evidence of clinical benefit. Most of the compounds sold as peptide therapy have never completed a phase 3 trial, and many have never been tested in humans at all. That does not make them useless — it makes their effect size, dosing, and long-term safety unknown.
The regulatory position matters. In 2023 the FDA moved a number of popular peptides, including BPC-157, ipamorelin, and epitalon, onto category 2 of the compounding bulk-substance lists, meaning significant safety risks were identified and they may not be compounded by 503A pharmacies. Compounds sold "for research use only" are not legal for human administration.
How to grade a peptide claim
- Is it FDA-approved for anything? If yes, read the label indication rather than the vendor page.
- Is there a randomized, placebo-controlled human trial? Ask for the citation, not a mechanism diagram.
- What is the sample size? Nineteen open-label participants is a hypothesis, not a result.
- Is it on an FDA compounding exclusion list?
- Who is dispensing it, and is the pharmacy 503A or 503B registered?
- Is there any long-term safety data, especially for growth-axis compounds?
Safety considerations that get skipped
Growth-hormone-axis peptides raise IGF-1. Elevated IGF-1 has been associated in epidemiological studies with higher risk of certain cancers, and there is no long-term interventional safety data in healthy adults. Anyone with an active or prior malignancy should not use them outside a specialist setting.
Sterility and identity are real risks with grey-market product. Independent testing of research-market peptides has repeatedly found incorrect content, contamination, and endotoxin. Injection-site infection and systemic reaction follow.
Interaction risk is under-studied. Most peptide vendors do not screen for concurrent medication, pregnancy, kidney disease, or malignancy history.
Kindr Health Peptide Evidence and Regulatory Status Dataset (2026)
Structured dataset grading major therapeutic peptides by human trial evidence, FDA approval and compounding status, effect size, and documented safety signals. Free to cite with attribution (CC BY 4.0).
| Trial | Year | n | Intervention | Comparator | Endpoint | Result |
|---|---|---|---|---|---|---|
| STEP 1Wilding JPH et al. N Engl J Med 2021. | 2021 | 1,961 | Semaglutide 2.4 mg | Placebo | Body weight at 68 weeks | −14.9% vs −2.4% |
| SURMOUNT-1Jastreboff AM et al. N Engl J Med 2022. | 2022 | 2,539 | Tirzepatide 15 mg | Placebo | Body weight at 72 weeks | −20.9% vs −3.1% |
| SELECTLincoff AM et al. N Engl J Med 2023. | 2023 | 17,604 | Semaglutide 2.4 mg | Placebo | Major adverse cardiovascular events | 20% relative risk reduction |
| Tesamorelin phase 3Falutz J et al. J Acquir Immune Defic Syndr 2010. | 2010 | 806 | Tesamorelin 2 mg daily | Placebo | Visceral adipose tissue at 26 weeks | −15.2% vs +5.0% |
| RECONNECTKingsberg SA et al. Obstet Gynecol 2019. | 2019 | 1,247 | Bremelanotide 1.75 mg as needed | Placebo | Desire and distress scores | Statistically significant, modest magnitude |
| FDA compounding reviewFDA 503A/503B bulk drug substances nominations review, 2023. | 2023 | 0 | BPC-157, ipamorelin, epitalon and others | Regulatory assessment | Bulk substance category | Placed in category 2 — significant safety risks identified |
The Kindr Peptide Candidacy Index
Live aggregate of anonymous peptide candidacy quiz submissions: mean risk score, goal specificity, concurrent medication burden, share reporting daily impact, and share not yet under clinical supervision.
The index publishes once at least 10 anonymous submissions are in (currently 0). Take the quiz above to contribute.
Self-reported, de-identified, aggregate-only. Journalists and researchers may cite with attribution to The Kindr Peptide Candidacy Index.
Want a straight answer about whether a peptide is right for you? Kindr clinicians will tell you when the evidence supports it — and when it does not.
Start your visit →Not ready? Ask Dot, our free AI menopause companion.
Frequently asked questions
Are peptides legal?
Approved peptide drugs are legal on prescription. Compounds sold "for research use only" are not legal for human administration, and several popular peptides were placed in FDA compounding category 2 in 2023, meaning licensed pharmacies may not compound them.
Does BPC-157 work?
There is substantial rodent data on tendon, ligament, and gut healing and no completed randomized controlled trial in humans. Its effect size, dose, and safety profile in people are unknown.
Are peptides safe?
It depends entirely on which peptide and where it came from. Approved peptides have characterised safety profiles. Research-market product carries risks of incorrect content, contamination, and endotoxin, and growth-axis peptides raise IGF-1 with no long-term safety data in healthy adults.
Which peptides have real evidence?
Semaglutide and tirzepatide have the strongest evidence by a wide margin. Tesamorelin has phase 3 data in a narrow indication, and bremelanotide has modest randomized evidence in premenopausal HSDD. Almost everything else is preclinical or small-sample.
Can peptides help with menopause symptoms?
No peptide is approved for vasomotor symptoms. The metabolic peptides can help with midlife weight and cardiometabolic risk in eligible patients, which is a different question from treating menopause itself.
What should I ask before starting?
Ask for the randomized human trial, the pharmacy registration, the batch testing certificate, the monitoring plan including IGF-1 where relevant, and what happens if it does not work.
Peptide therapy: evidence, legality, and safety
Evidence grading, regulation, safety, sourcing, and clinical use. Start anywhere.
Other Kindr symptom hubs
Continue across the Kindr entity graph
Related evidence, peptides, and clinical tools on the same topic.
- BPC-157 — tissue repair peptidePeptide
- GLP-1s in menopauseJournal
- TB-500 — recovery & repairPeptide
- Menopause & weight gainJournal
- GHK-Cu — regenerative copper peptidePeptide
- SemaglutidePeptide
Sources
- Wilding JPH et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med 2021.
- Jastreboff AM et al. Tirzepatide once weekly for the treatment of obesity. N Engl J Med 2022.
- Lincoff AM et al. Semaglutide and cardiovascular outcomes in obesity without diabetes. N Engl J Med 2023.
- Falutz J et al. Effects of tesamorelin on visceral adipose tissue. J Acquir Immune Defic Syndr 2010.
- Kingsberg SA et al. Bremelanotide for hypoactive sexual desire disorder. Obstet Gynecol 2019.
- US Food and Drug Administration. Bulk drug substances nominated for use in compounding — 503A and 503B category listings, 2023.
- Sikiric P et al. Stable gastric pentadecapeptide BPC 157 — preclinical review. Curr Pharm Des (preclinical evidence only).
Educational content only — not a substitute for professional medical advice, diagnosis, or treatment. The severity quiz is a screening aid, not a diagnosis. Reviewed by the Kindr Health clinical team · Last reviewed 2026-07-26.